Verastem (VSTM) Return on Capital Employed (2012 - 2026)
Verastem's quarterly Return on Capital Employed came in at 26.26% in Q1 2026, up 13556.0% year-on-year from N/an in Q1 2025, and up 16.8% quarter-over-quarter from 31.56% in Q4 2025.
Verastem has reported Return on Capital Employed for 15 years, with the latest figure at 26.26% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 13556.0% year-over-year to 26.26%; the trailing twelve-month figure through Mar 2026 stood at 26.26% (up 13556.0% YoY), and the FY2025 full-year result was 43.24%, up 7820.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 26.26%, up from 31.56% in the prior quarter.
- The five-year high for Return on Capital Employed was 26.26% in Q1 2026, with the low at 161.82% in Q1 2025.
- Average Return on Capital Employed over 5 years is 91.64%, with a median of 87.96% recorded in 2023.
- Year-over-year, Return on Capital Employed tumbled 9694 bps in 2024 and surged 13556 bps in 2026.
- Tracing VSTM's Return on Capital Employed over 5 years: stood at 89.59% in 2022, then rose by 25 bps to 67.43% in 2023, then slumped by 105 bps to 138.53% in 2024, then jumped by 77 bps to 31.56% in 2025, then rose by 17 bps to 26.26% in 2026.
- The last three Return on Capital Employed figures came in at 26.26% (Q1 2026), 31.56% (Q4 2025), and 126.33% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | -26.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.26% |
| Dec 31, 2025 | -31.56% |
| Sep 30, 2025 | -126.33% |
| Jun 30, 2025 | -137.79% |
| Mar 31, 2025 | -161.82% |
| Dec 31, 2024 | -138.53% |
| Sep 30, 2024 | -145.52% |
| Jun 30, 2024 | -117.19% |
| Mar 31, 2024 | -91.72% |
| Dec 31, 2023 | -67.43% |
| Sep 30, 2023 | -48.58% |
| Jun 30, 2023 | -54.74% |
| Mar 31, 2023 | -87.96% |
| Dec 31, 2022 | -89.59% |
| Sep 30, 2022 | -86.56% |
| Jun 30, 2022 | -79.08% |
| Mar 31, 2022 | -67.30% |
| Dec 31, 2021 | -66.98% |
| Sep 30, 2021 | -59.08% |
| Jun 30, 2021 | -27.02% |
| Mar 31, 2021 | -27.74% |
| Dec 31, 2020 | -29.21% |
| Sep 30, 2020 | -38.66% |
| Jun 30, 2020 | -61.31% |
| Mar 31, 2020 | -82.21% |
| Dec 31, 2019 | -95.26% |
| Sep 30, 2019 | -76.15% |
| Jun 30, 2019 | -64.47% |
| Mar 31, 2019 | -46.92% |
| Dec 31, 2018 | -49.08% |
| Sep 30, 2018 | -63.06% |
| Jun 30, 2018 | -81.34% |
| Mar 31, 2018 | -117.37% |
| Dec 31, 2017 | -114.27% |
| Sep 30, 2017 | -143.57% |
| Jun 30, 2017 | -80.16% |
| Mar 31, 2017 | -62.54% |
| Dec 31, 2016 | -49.11% |
| Sep 30, 2016 | -43.21% |
| Jun 30, 2016 | -47.96% |
| Mar 31, 2016 | -50.53% |
| Dec 31, 2015 | -53.75% |
| Sep 30, 2015 | -50.70% |
| Jun 30, 2015 | -45.03% |
| Mar 31, 2015 | -50.25% |
| Dec 31, 2014 | -60.19% |
| Sep 30, 2014 | -54.13% |
| Jun 30, 2014 | -46.55% |
| Mar 31, 2014 | -39.84% |
| Dec 31, 2013 | -34.20% |
| Sep 30, 2013 | -37.80% |
| Jun 30, 2013 | -48.51% |
| Mar 31, 2013 | -39.88% |
| Dec 31, 2012 | -34.48% |
| Sep 30, 2012 | -30.55% |
| Jun 30, 2012 | -22.76% |
| Mar 31, 2012 | -23.78% |